Immunotherapy of Hormone-Refractory Prostate Cancer With Antigen-Loaded Dendritic Cells
Top Cited Papers
- 1 December 2000
- journal article
- clinical trial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 18 (23) , 3894-3903
- https://doi.org/10.1200/jco.2000.18.23.3894
Abstract
PURPOSE: Provenge (Dendreon Corp, Seattle, WA) is an immunotherapy product consisting of autologous dendritic cells loaded ex vivo with a recombinant fusion protein consisting of prostatic acid pho...Keywords
This publication has 27 references indexed in Scilit:
- Cancer statistics, 2000CA: A Cancer Journal for Clinicians, 2000
- Systemic treatment for prostate cancerCancer Treatment Reviews, 1998
- Dendritic cells and the control of immunityNature, 1998
- Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm.Journal of Clinical Oncology, 1997
- Dendritic cells presenting tumor antigenCancer Immunology, Immunotherapy, 1996
- Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity.The Journal of Experimental Medicine, 1996
- Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunityNature Medicine, 1995
- Dendritic Cells as Carriers for a Cytotoxic T-Lymphocyte Epitope-Based Peptide Vaccine in Protection Against a Human Papillomavirus Type 16-Induced TumorJournal of Immunotherapy, 1995
- Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivoEuropean Journal of Immunology, 1994
- A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma.Journal of Clinical Oncology, 1985